Uncovering the interleukin‐12 pharmacokinetic desensitization mechanism and its consequences with mathematical modeling

Jonathon DeBonis,Omid Veiseh,Oleg A. Igoshin
DOI: https://doi.org/10.1002/psp4.13258
2024-10-18
CPT Pharmacometrics & Systems Pharmacology
Abstract:The cytokine interleukin‐12 (IL‐12) is a potential immunotherapy because of its ability to induce a Th1 immune response. However, success in the clinic has been limited due to a phenomenon called IL‐12 desensitization – the trend where repeated exposure to IL‐12 leads to reduced IL‐12 concentrations (pharmacokinetics) and biological effects (pharmacodynamics). Here, we investigated IL‐12 pharmacokinetic desensitization via a modeling approach to (i) validate proposed mechanisms in literature and (ii) develop a mathematical model capable of predicting IL‐12 pharmacokinetic desensitization. Two potential causes of IL‐12 pharmacokinetic desensitization were identified: increased clearance or reduced bioavailability of IL‐12 following repeated doses. Increased IL‐12 clearance was previously proposed to occur due to the upregulation of IL‐12 receptor on T cells that causes increased receptor‐mediated clearance in the serum. However, our model with this mechanism, the accelerated‐clearance model, failed to capture trends in clinical trial data. Alternatively, our novel reduced‐bioavailability model assumed that upregulation of IL‐12 receptor on T cells in the lymphatic system leads to IL‐12 sequestration, inhibiting the transport to the blood. This model accurately fits IL‐12 pharmacokinetic data from three clinical trials, supporting its biological relevance. Using this model, we analyzed the model parameter space to illustrate that IL‐12 desensitization occurs over a robust range of parameter values and to identify the conditions required for desensitization. We next simulated local, continuous IL‐12 delivery and identified several methods to mitigate systemic IL‐12 exposure. Ultimately, our results provide quantitative validation of our proposed mechanism and allow for accurate prediction of IL‐12 pharmacokinetics over repeated doses.
pharmacology & pharmacy
What problem does this paper attempt to address?